Advertisement

Neuroendocrine Disorders in Women

  • Alexandra J. Lovett
  • Whitney W. WoodmanseeEmail author
Chapter

Abstract

Neuroendocrine pathology related to disorders of the hypothalamus and pituitary cause a wide range of neurologic and psychiatric dysfunction. Neuroendocrine disorders can have similar implications in men and women; however, women have additional considerations given that dysfunction can lead to abnormal menses and infertility as well as certain disorders are more prevalent in women. This chapter will address the gender based concerns regarding: pituitary adenomas, Cushing’s syndrome, hypopituitarism, pituitary apoplexy and lymphocytic hypophysitis.

Keywords

Endocrine Neuroendocrine Pituitary adenoma Cushing’s disease Hypopituitarism Hyperprolactinemia 

References

  1. 1.
    Ezzat S, Asa SL, Couldwell WT, Barr CE, Dodge WE, Vance ML, McCutcheon IE. The prevalence of pituitary adenomas: a systematic review. Cancer. 2004;101(3):613–9.PubMedGoogle Scholar
  2. 2.
    Aflorei ED, Korbonits M. Epidemiology and etiopathogenesis of pituitary adenomas. J Neuro-Oncol. 2014;117:379–94.Google Scholar
  3. 3.
    Woodmansee WW, Carmichael J, Kelly D, Katzenslon L. American Association of Clinical Endocrinologists and American College of endocrinology disease state clinical review: postoperative management following pituitary surgery. Endocr Pract. 2015;21(7):832–8.PubMedGoogle Scholar
  4. 4.
    Bresson D, Herman P, Polivka M, Froelich S. Sellar lesions/pathology. Otolaryngol Clin N Am. 2016;29(1):63–93.Google Scholar
  5. 5.
    Horvath E, Kovacs K, Scheithauer BW. Pituitary hyperplasia. Pituitary. 1999;1(3–4):169–79.PubMedGoogle Scholar
  6. 6.
    Joshi AS, Woolf PD. Pituitary hyperplasia secondary to primary hypothyroidism: a case report and review of the literature. Pituitary. 2005;8(2):99–103.PubMedGoogle Scholar
  7. 7.
    Lopes MBS. The 2017 World Health Organization classification of tumors of the pituitary gland: a summary. Acta Neuropathol. 2017;134(4):521–35.PubMedGoogle Scholar
  8. 8.
    Freda PU, Beckers AM, Katznelson L, Molitch ME, Montori VM, Post KD, et al. Pituitary incidentaloma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(4):894–904.PubMedPubMedCentralGoogle Scholar
  9. 9.
    Casaneuva FF, Molitch ME, Schlechte JA, Abs R, Bonert V, Bronstein MD, et al. Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin Endocrinol. 2006;65(2):265–73.Google Scholar
  10. 10.
    Orija IB, Weil RJ, Hamrahian AH. Pituitary incidentaloma. Best Pract Res Clin Endocrinol Metab. 2012;26(1):47–68.PubMedGoogle Scholar
  11. 11.
    Klibanski A. Prolactinomas. New Engl J Med. 2010;362:1219–26.PubMedGoogle Scholar
  12. 12.
    Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM, Schlechte JA, Wass JAH. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(2):273–88.PubMedGoogle Scholar
  13. 13.
    Wong A, Eloy JA, Couldwell WT, Liu JK. Update on prolactinomas. Part 1: clinical manifestations and diagnostic challenges. J Clin Neurosci. 2015;22:1562–7.PubMedGoogle Scholar
  14. 14.
    Vilar L, Abucham J, Albuquerque JL, Araujo LA, Azevedo MF, Boguszewski CL, Casulari LA, Cunha Neto MBC, Czepielewski MA, Duarte FHG, Faria MDS, Gadelha MR, Garmes HM, Glezer A, Gurgel MH, Jallad RS, Martins M, Miranda PAC, Montenegro RM, Musolino NRC, Naves LA, Ribeiro-Oliveira Júnior A, Silva CMS, Viecceli C, Bronstein MD. Controversial issues in the management of hyperprolactinemia and prolactinomas – an overview by the Neuroendocrinology Department of the Brazilian Society of Endocrinology and Metabolism. Arch Endocrinol Metab. 2018;62(2):236–63.PubMedGoogle Scholar
  15. 15.
    Wong A, Eloy JA, Couldwell WT, Liu JK. Update on prolactinomas. Part 2: treatment and management strategies. J Clin Neurosci. 2015;22:1568–74.PubMedGoogle Scholar
  16. 16.
    Molitch ME. Pharmacologic resistance in prolactinoma patients. Pituitary. 2005;8:43–52.PubMedGoogle Scholar
  17. 17.
    Smith TR, Hulou MM, Huang KT, Gokoglu A, Cote DJ, Woodmansee WW, Laws ER. Current indications for the surgical treatment of prolactinomas. J Clin Neurosci. 2015;22:1785–91.PubMedGoogle Scholar
  18. 18.
    Maiter D. Prolactinoma and pregnancy: from the wish of conception to lactation. Ann Endocrinol (Paris). 2016;77(2):128–34.Google Scholar
  19. 19.
    Domingue ME, Devuyst F, Alexopoulou O, Corvilain B, Maiter D. Outcome of prolactinoma after pregnancy and lactation: a study on 73 patients. Clin Endocrinol. 2014;80(5):642–8.Google Scholar
  20. 20.
    Nieman LK, Biller BM, Findling JW, Newell-Price J, Savage MO, Stewart PM, Montori VM. The diagnosis of Cushing’s syndrome: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2008;93(5):1526–40.PubMedPubMedCentralGoogle Scholar
  21. 21.
    Pivonello R, De Leo M, Cozzolino A, Colao A. The treatment of Cushing’s disease. Endocr Rev. 2015;36(4):385–486.PubMedPubMedCentralGoogle Scholar
  22. 22.
    Van der Pas R, Leebeek FW, Hofland LJ, de Herder WW, Feelders RA. Hypercoagulability in Cushing’s syndrome: prevalence, pathogenesis, and treatment. Clin Endocrinol. 2013;78(4):481–8.Google Scholar
  23. 23.
    Sharma ST, Nieman LK, Feelders RA. Comorbidities in Cushing’s disease. Pituitary. 2015;18:188–94.PubMedPubMedCentralGoogle Scholar
  24. 24.
    Webb SM, Mo D, Lamberts SW, Melmed S, Cavagnini F, Pecori Giraldi F, Strasburger CJ, Zimmermann AG, Woodmansee WW, International HypoCCS Advisory Board. Metabolic, cardiovascular, and cerebrovascular outcomes in growth hormone-deficient subjects with previous Cushing’s disease or non-functioning pituitary adenoma. J Clin Endocrinol Metab. 2010;95(2):630–8.PubMedGoogle Scholar
  25. 25.
    Dekkers OM, Biermasz NR, Pereira AM, Roelfsema F, van Aken MO, Voormolen JH, Romijn JA. Mortality in patients treated for Cushing’s disease is increased, compared with patients treated for nonfunctioning pituitary macroadenoma. J Clin Endocrinol Metab. 2007;92(3):976–81.PubMedGoogle Scholar
  26. 26.
    Van Haalen FM, Broersen LH, Jorgensen JO, Pereira AM, Dekkers OM. Management of endocrine disease: mortality remains increased in Cushing’s disease despite biochemical remission: a systematic review and meta-analysis. Eur J Endocrinol. 2015;172(4):R143–9.PubMedGoogle Scholar
  27. 27.
    Papakokkinou E, Johansson B, Berglund P, Ragnarsson O. Mental fatigue and executive dysfunction in patients with Cushing’s syndrome in remission. Behav Neurol. 2015;2015:173653.PubMedPubMedCentralGoogle Scholar
  28. 28.
    Santos A, Crespo I, Aulinas A, Resmini E, Valassi E, Webb SM. Quality of life in Cushing’s syndrome. Pituitary. 2015;18(2):195–200.PubMedGoogle Scholar
  29. 29.
    Pires P, Santos A, Vives-Gilabert Y, Webb SM, Sainz-Ruiz A, Resmini E, Crespo I, de Juan-Delago M, Gómez-Anson B. White matter alterations in the brains of patients with active, remitted, and cured Cushing syndrome: a DTI study. AJNR Am J Neuroradiol. 2015;36(6):1043–8.PubMedGoogle Scholar
  30. 30.
    Andela CD, van Haalen FM, Ragnarsson O, Papakokkinou E, Johannsson G, Santos A, Webb SM, Biermasz NR, van der Wee NJ, Pereira AM. Mechanisms in endocrinology: Cushing’s syndrome causes irreversible effects on the human brain: a systematic review of structural and functional magnetic resonance imaging studies. Eur J Endocrinol. 2015;173(1):R1–14.PubMedGoogle Scholar
  31. 31.
    Santos A, Resmini E, Gómez-Ansón B, Crespo I, Granell E, Valassi E, Pires P, Vives-Gilabert Y, Martínez-Momblán MA, de Juan M, Mataró M, Webb SM. Cardiovascular risk and white matter lesions after endocrine control of Cushing’s syndrome. Eur J Endocrinol. 2015;173(6):765–75.PubMedGoogle Scholar
  32. 32.
    Loriaux DL. Diagnosis and differential diagnosis of Cushing’s syndrome. N Engl J Med. 2017;376(15):1451–9.PubMedGoogle Scholar
  33. 33.
    Nieman LK, Biller BM, Findling JW, Murad MH, Newell-Price J, Savage MO, Tabarin A. Treatment of Cushing’s syndrome: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2015;100(8):2807–31.PubMedPubMedCentralGoogle Scholar
  34. 34.
    Nieman LK. Update in the medical therapy of Cushing’s disease. Curr Opin Endocrinol Diabetes Obes. 2013;20(4):330–4.PubMedPubMedCentralGoogle Scholar
  35. 35.
    Colao AM, Petersenn S, Newell-Price J, Findling JW, Gu F, Maldonado M, Schoenherr U, Mills D, Salgado LR. Biller BKM for the Pasireotide B2305 Study Group. A 12 month phase 3 study of pasireotide in Cushing’s disease. N Engl J Med. 2012;366:914–24.PubMedGoogle Scholar
  36. 36.
    Kim SY. Diagnosis and treatment of hypopituitarism. Endocrinol Metab (Seoul). 2015;30(4):443–55.Google Scholar
  37. 37.
    Fleseriu M, Hashim IA, Karavitaki N, Melmed S, Murad MH, Salvatori R, et al. Hormonal replacement in hypopituitarism in adults: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2016;101(11):3888–921.PubMedGoogle Scholar
  38. 38.
    Laws ER, Iuliano SL, Cote DJ, Woodmansee W, Hsu L, Cho CH. A Benchmark for preservation of normal pituitary function after endoscopic transsphenoidal surgery for pituitary macroadenomas. World Neurosurg. 2016;91:371–5.PubMedGoogle Scholar
  39. 39.
    Richmond E, Rogol AD. Treatment of growth hormone deficiency in children, adolescents and at the transitional age. Best Pract Res Clin Endocrinol Metab. 2016;30(6):749–55.PubMedGoogle Scholar
  40. 40.
    Pfäffle R. Hormone replacement therapy in children: the use of growth hormone and IGF-I. Best Pract Res Clin Endocrinol Metab. 2015;29(3):339–52.PubMedGoogle Scholar
  41. 41.
    Molitch ME, Clemmons DR, Malozowski S, Merriam GR, Vance ML, Endocrine Society. Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(6):1587–609.PubMedGoogle Scholar
  42. 42.
    Jorgensen JOL, Juul A. Therapy of endocrine disease: growth hormone replacement therapy in adults: 30 years of personal clinical experience. Eur J Endocrinol. 2018;179(1):R47–56.PubMedGoogle Scholar
  43. 43.
    Leroy C, Karrouz W, Douillard C, Cao CD, Cortet C, Wemeau JL, Vantyghem MC. Diabetes insipidus. Ann Endocrinol. 2013;74:496–507.Google Scholar
  44. 44.
    Hall R, Manski-Nankervis J, Goni N, Davies MC, Conway GS. Fertility outcomes in women with hypopituitarism. Clin Endocrinol. 2006;65(1):71–4.Google Scholar
  45. 45.
    Capatina C, Inder W, Karavitaki N, Wass JA. Management of endocrine disease: pituitary tumour apoplexy. Eur J Endocrinol. 2015;172(5):R179–90.PubMedGoogle Scholar
  46. 46.
    Karaca Z, Laway BA, Dokmetas HS, Atmaca H, Kelestimur F. Sheehan syndrome. Nat Rev Dis Prim. 2016;2:16092.PubMedGoogle Scholar
  47. 47.
    Diri H, Tanriverdi F, Karaca Z, Senol S, Unluhizarci K, Durak AC, et al. Extensive investigation of 114 patients with Sheehan’s syndrome: a continuing disorder. Eur J Endocrinol. 2014;171(3):311–8.PubMedGoogle Scholar
  48. 48.
    Caturegli P, Newschaffer C, Olivi A, Pomper MG, Burger PC, Rose NR. Autoimmune hypophysitis. Endocr Rev. 2005;26(5):599–614.PubMedGoogle Scholar
  49. 49.
    Kyriacou A, Gnanalingham K, Kearney T. Lymphocytic hypophysitisis: modern day management with limited role for surgery. Pituitary. 2017;20(2):241–50.PubMedGoogle Scholar
  50. 50.
    Faje A. Hypophysitis: evaluation and management. Clin Diabetes Endocrinol. 2016;2:15.PubMedPubMedCentralGoogle Scholar
  51. 51.
    Joshi MN, Whitelaw BC, Palomar MT, Wu Y, Carroll PV. Immune checkpoint inhibitor-related hypophysitis and endocrine dysfunction: clinical review. Clin Endocrinol. 2016;85(3):331–9.Google Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Massachusetts General HospitalBostonUSA
  2. 2.Division of Endocrinology, Diabetes and MetabolismUniversity of FloridaGainesvilleUSA

Personalised recommendations